ABSI
Absci Corporation
$10.16
+1.22
(+13.65%)
Mkt Cap
1.72B
Volume
4,240,773
52W Range
2.24-12.06
Sector
Healthcare
Beta
2.28
EPS (TTM)
-0.80 USD
P/E Ratio
-4.15
Revenue (TTM)
1.56M USD
Rev Growth (5Y)
-10.1%
EPS Growth (5Y)
N/A
Company Description
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Net Income | (115.18M) | (103.11M) | (110.57M) | (104.90M) | (100.96M) | (14.35M) | (6.58M) |
| EPS | -0.84 | -0.94 | -1.20 | -1.15 | -1.11 | -0.54 | -0.07 |
| Free Cash Flow | (94.03M) | (72.81M) | (65.50M) | (97.51M) | (98.64M) | (13.15M) | (7.13M) |
| FCF / Share | -0.69 | -0.66 | -0.71 | -1.07 | -1.06 | -0.14 | -0.08 |
| Operating CF | (92.92M) | (72.40M) | (64.64M) | (81.34M) | (60.60M) | (10.97M) | (6.03M) |
| Total Assets | 216.30M | 213.61M | 217.30M | 321.01M | 426.19M | 88.57M | 19.47M |
| Total Debt | 5.30M | 10.11M | 15.88M | 22.98M | 20.01M | 14.50M | 6.02M |
| Cash & Equiv | 20.02M | 41.21M | 72.36M | 59.95M | 252.57M | 69.87M | 13.09M |
| Book Value | 189.45M | 179.13M | 176.18M | 274.41M | 366.11M | 67.00M | (41.16M) |
| Return on Equity | -0.61 | -0.58 | -0.63 | -0.38 | -0.28 | -0.21 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 318,000 | 215,000 | 650,000 | 378,000 | 593,000 | 1.18M | 665,000 | 1.70M | 1.27M | 898,000 | 338,000 | 744,000 |
| Net Income | (33.21M) | (29.60M) | (29.56M) | (28.71M) | (30.57M) | (26.35M) | (28.98M) | (27.40M) | (24.75M) | (21.98M) | (23.55M) | (21.99M) |
| EPS | -0.21 | -0.19 | -0.20 | -0.20 | -0.24 | -0.21 | -0.25 | -0.24 | -0.22 | -0.22 | -0.25 | -0.24 |
| Free Cash Flow | (27.57M) | (26.34M) | (29.08M) | (25.99M) | (17.10M) | (21.86M) | (16.99M) | (20.78M) | (17.18M) | (17.86M) | (14.94M) | (10.67M) |
| FCF / Share | -0.18 | -0.17 | -0.19 | -0.18 | -0.13 | -0.18 | -0.15 | -0.18 | -0.15 | -0.18 | -0.16 | -0.12 |
| Operating CF | (27.56M) | (26.31M) | (29.18M) | (25.03M) | (16.87M) | (21.84M) | (16.96M) | (20.73M) | (16.84M) | (17.86M) | (14.92M) | (10.36M) |
| Total Assets | 268.92M | 195.59M | 216.30M | 244.99M | 209.89M | 232.45M | 213.61M | 235.23M | 255.53M | 274.90M | 217.30M | 236.34M |
| Total Debt | 3.68M | 4.42M | 5.30M | 6.22M | 7.41M | 8.92M | 10.11M | 11.99M | 13.33M | 14.24M | 15.88M | 17.75M |
| Cash & Equiv | 107.86M | 8.63M | 20.02M | 9.48M | 38.02M | 46.99M | 41.21M | 38.20M | 42.94M | 58.83M | 72.36M | 69.73M |
| Book Value | 246.13M | 171.97M | 189.45M | 210.34M | 173.37M | 198.80M | 179.13M | 201.34M | 221.49M | 240.11M | 176.18M | 196.42M |
| Return on Equity | -0.13 | -0.17 | -0.16 | -0.14 | -0.18 | -0.13 | -0.16 | -0.14 | -0.11 | -0.09 | -0.13 | -0.11 |
ABSI News
Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE
Absci to Participate in Upcoming Investor Conferences
AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma